Campaign or Project PR

The Brief

BiomeBank aimed to transition from a South Australian stool bank to a globally recognized biotechnology company. To support this, two strategic announcements were launched:

• A successful capital raise to scale operations and drug development.

• Anticipated TGA approval for BiomeBank’s microbiome-based therapy.

The Challenge

BiomeBank needed to reposition itself as a world-leading biotechnology company while securing visibility among investors and pharmaceutical companies. Key challenges included:

• Establishing credibility: Educating stakeholders on BiomeBank’s unique live biotherapeutic products.

• Market competition: Differentiating BiomeBank’s therapies in a growing biotech sector.

• Regulatory hurdles: Ensuring communications aligned with TGA approval requirements.

• Media saturation: Cutting through a cluttered media landscape during an election period.

The Results

• Successful capital raise: attracted institutional investors, securing funding to scale manufacturing and develop next-generation therapies.

• Enhanced industry positioning: repositioned BiomeBank as a global leader in microbiome-based drug development.

• Mainstream and trade media coverage: Secured features in AFR, The Australian, Fierce Biotech, and InvestorDaily, amplifying credibility.

• Investor & Pharma Engagement: increased awareness among pharmaceutical companies and investors, driving strategic partnerships.

• Anticipated TGA approval messaging: positioned BiomeBank’s therapy as a groundbreaking treatment for gut disease, reinforcing its market leadership.

Featured in